- 全部删除
您的购物车当前为空
USP1-IN-9 (Compound 1m) 是一种可逆且非竞争性的泛素化特异性酶 (USP1) 抑制剂,其IC50值为8.8 nM。该化合物基于ML323和KSQ-4279的结构设计,被合成为吡啶[2,3-d]嘧啶-7(8H)- 1衍生物。USP1-IN-9 有效抑制USP1/UAF,并对乳腺癌细胞展现出强大的抗增殖能力。与PARP抑制剂奥拉帕利布联合使用时,可增强对MDA-MB-436/OP细胞的杀伤效果,预示其在癌症研究领域的潜在应用。
USP1-IN-9 (Compound 1m) 是一种可逆且非竞争性的泛素化特异性酶 (USP1) 抑制剂,其IC50值为8.8 nM。该化合物基于ML323和KSQ-4279的结构设计,被合成为吡啶[2,3-d]嘧啶-7(8H)- 1衍生物。USP1-IN-9 有效抑制USP1/UAF,并对乳腺癌细胞展现出强大的抗增殖能力。与PARP抑制剂奥拉帕利布联合使用时,可增强对MDA-MB-436/OP细胞的杀伤效果,预示其在癌症研究领域的潜在应用。

USP1-IN-9 相关产品
| 产品描述 | USP1-IN-9 (Compound 1m) is a reversible and non-competitive inhibitor of ubiquitin-specific protease (USP1) with an IC50 value of 8.8 nM. It is synthesized based on the structures of ML323 and KSQ-4279 as a pyrido[2,3-d]pyrimidin-7(8H)-one derivative. USP1-IN-9 exhibits excellent inhibition of USP1/UAF and demonstrates strong antiproliferative effects on breast cancer cells. When combined with the PARP inhibitor olaparib, USP1-IN-9 enhances the cytotoxic effect on MDA-MB-436/OP cells. USP1-IN-9 holds potential for research in the field of cancer. |
| 靶点活性 | USP1:8.8 nM |
| 体外活性 | USP1-IN-9(20,100,500 nM,24 h)在非小细胞肺癌细胞(NSCLC)中以剂量依赖的方式提升了单泛素化增殖细胞核抗原(Ub-PCNA)的水平,并且在低至20 nM的浓度下也能表现出Ub-增殖细胞核抗原的增加。 |
| 体内活性 | USP1-IN-9 (10 mg/kg,i.g.) 能快速被雄性ICR小鼠吸收,且显示出良好的代谢稳定性。USP1-IN-9在小鼠体内的药动学参数如下:剂量 (mg/kg, po)为10,T max (h)为0.25,C max (ng/mL)达到4780 ± 2090,AUC 0-t (ng·h/mL)为35,800 ± 13,500,T 1/2 (h)为7.61 ± 4.67。 |
| 存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
评论内容